Scientists report advantage of Eli Lilly bone drug over rival

Eli Lilly's treatment Forteo improved spine and hip bone density more effectively than Merck & Co.'s Fosamax, according to a study of 428 patients with osteoporosis. Forteo enhanced the bone density of the lumbar spine by 7.2% compared to 3.4% for Fosamax recipients, and also increased hip bone density by 3.8% compared to 2.4% for patients using Merck's candidate, researchers in Alabama found.

View Full Article in:

Indianapolis Star (tiered subscription model), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC